Rebekah Sayers

How is EAD transforming from a niche technique into a cornerstone of daily metabolomics and lipidomics research?

Aug 27, 2025 | Blogs, Life Science Research | 0 comments

Introduction

With the launch of the ZenoTOF 8600 system, EAD has taken a significant leap forward in becoming a routine tool for metabolomics and lipidomics workflows. Building on the foundation laid by the ZenoTOF 7600 system, the 8600 system introduces enhanced sensitivity, function speed improvements, and multimodal capabilities that make EAD more practical and scalable for daily use. This blog explores how these advancements are transforming EAD from a specialized technique into a robust and accessible solution for high-throughput structural analysis, enabling researchers to unlock deeper insights with greater efficiency.

The evolution of EAD

The introduction of the ZenoTOF 7600 system marked a significant milestone in mass spectrometry. This system integrates EAD, providing a new paradigm for fragmentation technology. Unlike traditional methods like collision-induced dissociation (CID), which primarily breaks weaker bonds, EAD can cleave stronger bonds, offering more detailed structural information. This capability is particularly valuable for analyzing complex biological molecules such as lipids and metabolites.

Dr. Michael Witting, Deputy Head of the Metabolomics and Proteomics Core at Helmholtz Munich, highlighted the importance of EAD in a recent webinar. He stated, “Luckily, EAD has been brought up to the field. Now with EAD, we start to move closer to lipid biology, which enables us to have detailed lipid structure identification”.

How researchers apply EAD in daily workflows

Many researchers have rapidly adopted EAD in their daily workflows, leveraging its advanced capabilities to enhance their analyses. The ZenoTOF 7600 and 8600 systems’ tunable electron beam allows for precise fragmentation, making them suitable for a wide range of applications. Dr. Witting mentioned, “Lipids have a high structural diversity even within a single lipid class… EAD started to help us. So, we have been using the ZenoTOF since 2021, with the EAD technology, with EAD fragmentation”.

In his blog, Prof. Nicola Zamboni discussed how EAD on the ZenoTOF 7600 system can fragment virtually all C-C bonds in the fatty acid chain of singly charged lipids, providing detailed structural information that CID cannot. He explains, “One of the grand challenges in metabolomics using mass spectrometry (MS) is the limited and somewhat redundant information provided by collision-induced dissociation (CID). CID is incredibly versatile and quick, but tends to fragment weaker bonds, such as C-O bonds. This bias allows us to observe fragments indicative of specific functional groups easily… Unfortunately, CID struggles to break stronger bonds like C-C or C=C, which are crucial for resolving the structure in parts of the molecule dominated by hydrocarbons”.

Enhancing routine EAD workflows with the ZenoTOF 8600 system

The ZenoTOF 8600 system represents a transformative step in making electron-activated dissociation (EAD) a practical tool for routine metabolomics and lipidomics workflows. With up to 10x greater MS/MS sensitivity and the ability to perform EAD at LC-compatible speeds (10–15 ms accumulation times), the system removes previous limitations around throughput and structural resolution. As Prof Zamboni explains, “With the 8600 system, we can now do EAD at 10–15 milliseconds. That’s LC-compatible. That’s routine.”

This leap in performance enables researchers to confidently apply EAD in high-throughput workflows, including 2-minute LC gradients, without sacrificing data quality. “We’re seeing fragmentation across the full lipid spectrum, even in ultra-fast gradients. That’s a game-changer,” Prof Zamboni adds.

The system’s ability to resolve previously indistinguishable isomers further elevates its utility in lipidomics: “We’re not just identifying more lipids; we’re resolving isomers that were previously indistinguishable.” These innovations make EAD not only more accessible and scalable but also robust and versatile, ideal for integration into routine omics pipelines. As Zamboni concludes, “EAD used to be a niche capability. With the 8600 system, it’s now a routine tool, fast, sensitive, and scalable.”

Supporting the integration of EAD into routine workflows

Several developments support the integration of EAD into routine workflows:

Annotation tools: Tools like the EIEIO Annotation Tool provide comprehensive platforms for annotating mass spectrometry data, supporting the integration of EAD data, and offering features for detailed structural elucidation.
Data analysis software: Advanced software solutions, such as MS-Dial and SCIEX OS 4.0, facilitate automated data analysis, enhancing the efficiency and accuracy of EAD-based workflows.
Collaborative projects: Initiatives like Dr. Witting’s team’s upcoming library release on GitHub provide high-quality data and tools for metabolite and lipid identification, supporting the integration of EAD into routine workflows.

Looking ahead: Future trends and applications of EAD

Prof Nicola Zamboni has shown “The combination of Zeno trap and EAD gives us the confidence to go untargeted—and still get meaningful structural data.” The future of EAD in metabolomics and lipidomics looks promising, with several emerging trends and applications:

Integration with Artificial Intelligence (AI): AI and machine learning algorithms can analyze the complex data generated by EAD, leading to more accurate and faster identification of metabolites and lipids. This integration can also help predict unknown compounds and understand their biological significance.
Clinical applications: EAD has the potential to be used in clinical diagnostics, particularly in identifying disease biomarkers. Its ability to provide detailed structural information can aid in the early detection and monitoring of diseases such as cancer, diabetes, and cardiovascular disorders.
Environmental monitoring: EAD can be applied to environmental studies to analyze pollutants and their metabolites. This can help understand pollutants’ impact on ecosystems and human health, leading to better regulatory policies and remediation strategies.
Personalized medicine: The detailed molecular information provided by EAD can be used to tailor treatments to individual patients based on their unique metabolic and lipidomic profiles. This can improve the efficacy of treatments and reduce adverse effects.
Expansion to other omics: Beyond metabolomics and lipidomics, EAD can be integrated into other omics fields such as proteomics and glycomics. This can provide a more comprehensive understanding of biological systems and their interactions.

Conclusion: EAD as a cornerstone of routine omics research

Electron-activated dissociation (EAD) has evolved from a novel fragmentation technique into a powerful tool for routine metabolomics and lipidomics workflows. With the launch of the ZenoTOF 8600 system, EAD is now more accessible, scalable, and robust than ever before. The system’s enhanced sensitivity, speed, and multimodal capabilities, especially its ability to perform EAD at LC-compatible timescales and support high-throughput DIA workflows, remove previous barriers to adoption. Researchers can now confidently integrate EAD into daily analyses, unlocking deeper structural insights across a broader range of compounds. As the technology continues to mature, EAD is poised to become a cornerstone of routine omics workflows, driving innovation in clinical, environmental, and personalized research.

As Prof Zamboni concluded, “It’s not just about more data, it’s about better data. Cleaner spectra, higher confidence, and more meaningful biology.”

Additional resources for exploring EAD and the ZenoTOF 8600 system

Watch Dr. Nicola Zamboni’s talk from the ASMS launch to gain deeper insights into the advancements and applications of EAD in metabolomics and lipidomics. Watch now.

Access Dr. Nicola Zamboni’s data from the ZenoTOF 8600 system to experience firsthand the potential of EAD in lipidomics. Access now. https://polybox.ethz.ch/index.php/s/cS36y4bfawPAdTH

Read Dr. Nicola Zamboni’s blog to gain deeper insights into the advancements and applications of EAD in metabolomics and lipidomics. Read now. On the benefits and role of electron-induced dissociation in lipidomics

Watch Dr. Michael Witting’s webinar to gain deeper insights into the advancements and applications of EAD in metabolomics and lipidomics. Watch now.

References

ADC analytics FAQs: Answering the most common questions about ADC characterization

Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing classes of biotherapeutics, combining the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads. However, this unique architecture also introduces significant analytical complexity. From drug-to-antibody ratio (DAR) distributions and charge variants to conjugation sites and structural modifications, ADCs present multiple, interconnected sources of heterogeneity that must be understood to ensure product quality and performance.

Sterile but toxic: Cereulide detection in food matrices

In a recent webinar, Ming Gao, Ph.D., Senior Research Chemist at Mérieux NutriSciences, explored the growing challenge of cereulide contamination in food products and the analytical strategies needed to detect this heat-stable toxin at trace levels. The session examined how LC-MS/MS can help laboratories overcome the limitations of traditional microbiological screening and meet emerging regulatory requirements.

How SCIEX Now empowers mass spec users to work with more control, clarity and confidence

In this interview, Andy Wilcox, Senior Market Development Manager, Aftermarket and Software, speaks with Susanna Baqué, Senior Director of Global Customer Experience, about how SCIEX Now gives customers one connected digital workspace to manage instruments, reduce time spent searching for information, resolve issues faster and keep their laboratory running more efficiently and with greater confidence.

Posted by

Rebekah Sayers

I developed a foundational understanding of biochemistry during my undergraduate studies before gaining a masters in molecular and cellular biophysics, and finally obtaining my Ph.D conducting in-depth proteomics research in peanut allergy. I started at SCIEX in the applications support team, later being promoted to the application lead for life science research in EMEAI. I am currently leading global strategic marketing efforts, contributing to the advancement of small molecule OMICS. This role is pivotal in bridging the gap between scientific innovation and market demand, ensuring that products and workflows not only meet the needs of the market but also stand out in a competitive landscape.

0 Comments